Health

Trial Shows mRNA Vaccine Boosts Pancreatic Cancer Survival

Are mRNA neoantigen vaccines a breakthrough rewriting pancreatic cancer survival or a dangerous distraction masking the true drivers of rising cases?

Published 2 hours ago

Trial Shows mRNA Vaccine Boosts Pancreatic Cancer Survival

story

Above: A laboratory worker prepares messenger RNA (mRNA) on Nov. 18, 2025. Image credit: Jean-Francois Monier/AFP/Getty Images

The Spin

Pro-establishment narrative

mRNA neoantigen vaccines are rewriting the prognosis for pancreatic cancer, a disease that kills over 87% of patients within five years. Nearly all trial responders are still alive at six years, with 98% of induced T cells being newly generated. This means the immune system genuinely learned to recognize and fight the cancer. Combined with breakthroughs like daraxonrasib targeting KRAS G12D, the survival odds for pancreatic cancer are finally shifting.

Dr. Richard Hirschson on X

Bo Wang on X

Establishment-critical narrative

Personalized mRNA cancer vaccines are being celebrated while the root cause — repeated COVID infection — keeps driving pancreatic cancer rates higher. Studies show mRNA-boosted pancreatic cancer patients lived half as long as non-boosted patients, with cancer death risk jumping 72%. Pushing mRNA as the cure while ignoring ongoing mass reinfection is a dangerous distraction that benefits pharmaceutical profits far more than patients.

Laura Miers on X

Nicolas Hulscher on X